ER
Therapeutic Areas
Cardurion Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| PDE9 Inhibitor | Heart Failure (HFrEF and HFpEF) | Clinical |
| CaMKII Inhibitor | Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), Heart Failure, Atrial Fibrillation | Clinical |
Leadership Team at Cardurion Pharmaceuticals
PS
Peter S. Lawrence, J.D.
President and CEO
ME
Michael E. Mendelsohn, M.D.
Founder and Chief Strategy Officer
HK
Howard K. Surks, M.D.
Chief Medical and Scientific Officer
CN
Charlotte Newman
Chief Business & Operations Officer